0      0


AM21-56: COVID-19 Convalescent Plasma: Impact on Donation Safety and Eligibility


‐ Oct 19, 2021 9:00pm

Expiration Date: Dec 31, 2023


Credits: None available.

COVID-19 convalescent plasma (CCP) from individuals recently recovered from SARS-CoV-2 infection is an important therapeutic option for individuals at risk for severe complications from COVID-19. Ensuring donor safety is of paramount importance for collection of CCP. Common donor adverse events (DAEs) generally involve complications such as vasovagal reactions, local arm pain or hematomas, as well as reactions related to apheresis collections. Other unique aspects related to donor health in individuals recovered from COVID-19 must also be considered, including donors who have received COVID-19 Convalescent Plasma (CCP) or monoclonal antibody therapy, as well as SARS-CoV-2 vaccination post-recovery. The AABB Donor Hemovigilance Working Group will share the results from their multi-institutional study analyzing key safety metrics related to the collection of CCP. Join this session to learn about new insights on donor hemovigilance gleaned from recent efforts collecting CCP.

To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.

Learning Objectives:

  • Identify challenges encountered by blood centers with the collection of CCP donors related to the impact of unique eligibility requirements
  • List examples of common blood center protocols to improve donation safety during the COVID-19 pandemic
  • Recognize differences in risks factors for donor adverse events (DAEs) in CCP donors compared to conventional plasma donors identified in a large multicenter study
  • Define acceptance criteria for collection of COVID-19 Convalescent Plasma (CCP) and variations between organizations screening for suitable donors

Speaker(s):

Moderator(s):

Disclosures

  • Nancy Van Buren, MD:
    Nothing to Disclose
  • Jed Gorlin, MD, MBA:
    Nothing to Disclose
  • Mary Townsend, MD:
    Consultant: Cerus: Medical Advisory Board, non-paid: Terumo

Tags:

donor hemovigilance noninfectious adverse events blood bankblood center donor collection testing processing

All relevant financial relationships have been mitigated. By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.

Credits Available


AM21-56: COVID-19 Convalescent Plasma: Impact on Donation Safety and Eligibility Evaluation